Letrofam (Letrozole)

Letrofam, an aromatase inhibitor, is employed in the management of estrogen‑driven breast cancer.

• Postmenopausal estrogen receptor‑positive breast cancer: Reduces tumor growth by lowering circulating estrogen levels.
• Adjuvant treatment of breast cancer: Decreases risk of disease recurrence after surgery.
• Metastatic breast cancer: Provides disease control in advanced hormone‑sensitive tumors.

• Letrozole reversibly binds to the aromatase enzyme, blocking the conversion of androgens to estrogens in peripheral tissues. This inhibition markedly lowers systemic estrogen concentrations, depriving estrogen‑dependent tumor cells of a growth stimulus and thereby slowing or halting disease progression.

Letrofam may cause a range of adverse reactions.

Common Side Effects

• Hot flashes: Sudden feeling of warmth, often with sweating.
• Joint and muscle pain: Aching discomfort in limbs or back.
• Fatigue: Persistent tiredness not relieved by rest.
• Nausea: Mild to moderate upset stomach.
• Headache: Pressure or throbbing pain in the head.
• Increased cholesterol: Elevated blood lipid levels.

Serious or Rare Side Effects

• Severe liver injury: Jaundice, dark urine, abdominal pain.
• Allergic reactions: Rash, itching, swelling, or difficulty breathing.
• Pulmonary embolism: Sudden shortness of breath, chest pain.
• Osteoporotic fractures: Bone weakening leading to breaks.
• Severe hypertension: Markedly high blood pressure.
• Deep vein thrombosis: Swelling and pain in a limb.

Patients should be monitored for safety considerations before and during therapy.

• Bone health monitoring: Assess bone mineral density regularly because estrogen depletion can accelerate bone loss.
• Lipid profile assessment: Check cholesterol levels periodically as they may rise.
• Liver function tests: Perform baseline and periodic liver enzyme measurements.
• Cardiovascular risk evaluation: Review blood pressure and cardiovascular history.
• Pregnancy avoidance: Do not use in women who are pregnant or may become pregnant.
• Store at ambient temperature: Keep below 25°C in the original container, protected from moisture and direct sunlight.

Letrofam can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Estrogen replacement therapy: Counteracts aromatase inhibition and may diminish therapeutic benefit.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): Can raise letrozole plasma levels, increasing risk of adverse effects.

Moderate Interactions (Monitor Closely)

• CYP2C19 inhibitors (e.g., fluconazole): May modestly increase letrozole exposure.
• Warfarin: Potential for altered anticoagulant effect; monitor INR.
• Statins: Possible additive impact on liver enzymes; check hepatic function.
• Antidepressants (SSRIs): May affect hormone metabolism; observe clinical response.